The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCPT.L Regulatory News (CPT)

  • There is currently no data for CPT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

22 Dec 2017 11:30

RNS Number : 2392A
Concepta PLC
22 December 2017
 

22 December 2017

 

Concepta plc

 

("Concepta" or the "Company")

 

Trading update

 

Pursuant to the statement made on 6 November and 13 November 2017, Concepta plc, the UK healthcare company and developer of a proprietary platform and suite of products targeted at the mobile health market with a primary focus on women's fertility, provides shareholders today with an update on trading ahead of its 31 December 2017 year end.

 

Due to a labelling quality issue with the Company's manufacturer in China following its recent ramp up of production, the Company did not receive sufficient monitors to meet the order announced on 13 November. The majority of this order will now be delivered in January 2018. This issue, although now rectified, will have a distortion on the 2017 revenues which are now expected to be around £100,000. The Company will now recognise the majority of the revenue relating to this order in Q1 2018.

 

Orders have been increasing in the last few months of 2017 and with further new distributors likely to be appointed in the New Year the Board expects the delayed revenue referred to above to be additive to the 2018 budget. Following its recent fundraise, the Company has sufficient cash to meet its working capital requirements through 2018.

 

Erik Henau, CEO of Concepta plc said: "The team on the ground in China have been working hard over recent months to address issues identified within our supply chain as we continue to scale up production. The China team will have the support of David Darrock as Chief Operating Officer who has experience in the move from assembling products in a laboratory environment to full scale commercial manufacturing. We enforce strict quality control standards on our products and as such we have commenced a full supply chain evaluation with our suppliers and have implemented a number of measures to strengthen processes, for which we are already seeing significant improvements. Despite the impact of these issues I am confident that, following the improvements made, we are entering 2018 in a much stronger position."

 

ENDS

 

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

 

Beaufort Securities Limited (Joint Broker)

Jon Belliss

Tel: +44 (0)20 7382 8300

 

Novum Securities (Joint Broker)

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

 

About Concepta Plc:

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility* in women.

 

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH and hCG* hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

 

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.

 

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

 

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBBBDDCDDBGRD
Date   Source Headline
3rd Jul 20159:29 amRNSHolding(s) in Company
30th Jun 201511:21 amRNSProposed Settlement of Director Debt
30th Jun 201510:49 amRNSResult of AGM and Capital Reorganisation
9th Jun 20151:09 pmRNSOperational Update: Namibia
4th Jun 20151:26 pmRNSNotice of AGM and Proposed Capital Reorganisation
2nd Jun 20157:00 amRNSOperational update Oman
1st Jun 20157:00 amRNSConditional Subscription Update
22nd May 20154:29 pmRNSConditional Subscription
18th May 201512:00 pmRNSResult of General Meeting
28th Apr 201511:10 amRNSConditional Subscription - Posting of Circular
7th Apr 20157:00 amRNSFinal results year ended 31 December 2014
2nd Apr 20157:00 amRNSOperational Update: Sultanate of Oman
17th Mar 20155:36 pmRNSConditional Share Subscription
8th Jan 20157:00 amRNSOperational Update
31st Dec 201410:49 amRNSTotal Voting Rights
13th Nov 20147:00 amRNSBoard Changes, Subscription and Issue of Equity
28th Oct 20147:00 amRNSAppointment of Geological Advisor
28th Oct 20147:00 amRNSOperational Update
27th Oct 20141:18 pmRNSHolding(s) in Company
17th Sep 20145:28 pmRNSAppointment of Joint Broker
10th Sep 20147:00 amRNSInterim Results
31st Jul 20144:45 pmRNSTotal Voting Rights
22nd Jul 201410:48 amRNSOperational Update: Namibia
4th Jul 20146:08 pmRNSHolding(s) in Company
4th Jul 201412:54 pmRNSHolding(s) in Company
27th Jun 20143:17 pmRNSResult of AGM
27th Jun 20147:00 amRNSPlacing
26th Jun 20142:00 pmRNSPreliminary unaudited results
24th Jun 201411:08 amRNSAGM
16th May 20147:00 amRNSOperational Update: Sultanate of Oman
24th Mar 20147:00 amRNSFarm-out Update: Namibia and Zambia
11th Mar 20145:34 pmRNSBoard Change
4th Feb 20147:00 amRNSOperational Update: Namibia
29th Jan 201411:49 amRNSHolding(s) in Company
29th Jan 20147:00 amRNSOperational Update: Namibia
27th Jan 20149:24 amRNSCompletion of Equity Swap and Payment Acceleration
19th Dec 20137:00 amRNSAppointment of Joint Broker
11th Nov 20137:00 amRNSCorporate Activities Update
22nd Oct 20133:29 pmRNSGrant of Options and Opening of London Office
25th Sep 20137:00 amRNSInterim Results for the six months to 30 June 2013
23rd Sep 20137:00 amRNSOperational Update: Zambia
16th Sep 20137:00 amRNSOperational Update: Sultanate of Oman
9th Sep 20137:00 amRNSOperational Update: Namibia
31st Jul 20137:00 amRNSOperational Update: Namibia
23rd Jul 20137:00 amRNSOperational Update: Zambia
16th Jul 20137:00 amRNSAppointment of Exploration Manager
5th Jul 20137:00 amRNSAdmission and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.